51. 全身性強皮症 Scleroderma Clinical trials / Disease details
臨床試験数 : 523 / 薬物数 : 608 - (DrugBank : 156) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 215
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00764309 (ClinicalTrials.gov) | January 2009 | 1/10/2008 | Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis | An Open Label Study to Evaluate the Safety of Dasatinib in the Treatment of Scleroderma Pulmonary Interstitial Fibrosis | Scleroderma | Drug: dasatinib | Bristol-Myers Squibb | NULL | Completed | 18 Years | N/A | All | 47 | Phase 1/Phase 2 | United States |